Jeffrey V. Poulton's most recent trade in CervoMed Inc was a trade of 8,100 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 23, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CervoMed Inc | Jeffrey V. Poulton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2025 | 8,100 | 8,100 | - | - | Stock Option (Right to Buy) | |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 15,117 | 49,015 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 9,800 | 9,800 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 243.36 per share. | 03 Mar 2025 | 382 | 48,283 (0%) | 0% | 243.4 | 92,964 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 242.37 per share. | 03 Mar 2025 | 350 | 48,665 (0%) | 0% | 242.4 | 84,830 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 244.41 per share. | 03 Mar 2025 | 258 | 48,025 (0%) | 0% | 244.4 | 63,058 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 245.26 per share. | 03 Mar 2025 | 189 | 47,836 (0%) | 0% | 245.3 | 46,354 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 246.18 per share. | 03 Mar 2025 | 77 | 47,759 (0%) | 0% | 246.2 | 18,956 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 247.29 per share. | 03 Mar 2025 | 7 | 47,752 (0%) | 0% | 247.3 | 1,731 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 248.00 per share. | 03 Mar 2025 | 1 | 47,751 (0%) | 0% | 248 | 248 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 1,908 | 1,908 | - | - | Restricted Stock Units | |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 1,908 | 34,694 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 242.44 per share. | 27 Feb 2025 | 300 | 34,078 (0%) | 0% | 242.4 | 72,732 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 241.51 per share. | 27 Feb 2025 | 127 | 34,378 (0%) | 0% | 241.5 | 30,672 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 243.23 per share. | 27 Feb 2025 | 121 | 33,957 (0%) | 0% | 243.2 | 29,431 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 240.32 per share. | 27 Feb 2025 | 78 | 34,505 (0%) | 0% | 240.3 | 18,745 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 244.10 per share. | 27 Feb 2025 | 59 | 33,898 (0%) | 0% | 244.1 | 14,402 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 236.50 per share. | 27 Feb 2025 | 42 | 34,652 (0%) | 0% | 236.5 | 9,933 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 239.17 per share. | 27 Feb 2025 | 35 | 34,583 (0%) | 0% | 239.2 | 8,371 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 238.32 per share. | 27 Feb 2025 | 34 | 34,618 (0%) | 0% | 238.3 | 8,103 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 3,109 | 33,753 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 253.37 per share. | 13 Feb 2025 | 239 | 33,297 (0%) | 0% | 253.4 | 60,555 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 252.50 per share. | 13 Feb 2025 | 217 | 33,536 (0%) | 0% | 252.5 | 54,793 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 254.35 per share. | 13 Feb 2025 | 160 | 33,137 (0%) | 0% | 254.4 | 40,696 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 256.29 per share. | 13 Feb 2025 | 78 | 32,991 (0%) | 0% | 256.3 | 19,991 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 255.56 per share. | 13 Feb 2025 | 68 | 33,069 (0%) | 0% | 255.6 | 17,378 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 258.06 per share. | 13 Feb 2025 | 47 | 32,907 (0%) | 0% | 258.1 | 12,129 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 261.46 per share. | 13 Feb 2025 | 37 | 32,823 (0%) | 0% | 261.5 | 9,674 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 257.51 per share. | 13 Feb 2025 | 37 | 32,954 (0%) | 0% | 257.5 | 9,528 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 260.57 per share. | 13 Feb 2025 | 30 | 32,860 (0%) | 0% | 260.6 | 7,817 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 264.85 per share. | 13 Feb 2025 | 20 | 32,786 (0%) | 0% | 264.9 | 5,297 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 259.71 per share. | 13 Feb 2025 | 17 | 32,890 (0%) | 0% | 259.7 | 4,415 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 263.35 per share. | 13 Feb 2025 | 17 | 32,806 (0%) | 0% | 263.4 | 4,477 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Nov 2024 | 3,434 | 32,326 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | V. Poulton Jeffrey | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 251.42 per share. | 25 Nov 2024 | 945 | 30,741 (0%) | 0% | 251.4 | 237,592 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 250.68 per share. | 25 Nov 2024 | 364 | 31,686 (0%) | 0% | 250.7 | 91,248 | Common Stock |
| Alnylam Pharmaceuticals Inc | V. Poulton Jeffrey | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 249.60 per share. | 25 Nov 2024 | 246 | 32,050 (0%) | 0% | 249.6 | 61,402 | Common Stock |
| Alnylam Pharmaceuticals Inc | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 252.27 per share. | 25 Nov 2024 | 97 | 30,644 (0%) | 0% | 252.3 | 24,470 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 247.77 per share. | 25 Nov 2024 | 30 | 32,296 (0%) | 0% | 247.8 | 7,433 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 3,278 | 30,497 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 229.93 per share. | 24 Jun 2024 | 304 | 29,674 (0%) | 0% | 229.9 | 69,899 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 229.06 per share. | 24 Jun 2024 | 266 | 29,978 (0%) | 0% | 229.1 | 60,930 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 232.54 per share. | 24 Jun 2024 | 216 | 29,359 (0%) | 0% | 232.5 | 50,229 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 234.66 per share. | 24 Jun 2024 | 185 | 29,059 (0%) | 0% | 234.7 | 43,412 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 235.19 per share. | 24 Jun 2024 | 167 | 28,892 (0%) | 0% | 235.2 | 39,277 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 228.30 per share. | 24 Jun 2024 | 129 | 30,244 (0%) | 0% | 228.3 | 29,451 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 233.53 per share. | 24 Jun 2024 | 115 | 29,244 (0%) | 0% | 233.5 | 26,856 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 231.59 per share. | 24 Jun 2024 | 99 | 29,575 (0%) | 0% | 231.6 | 22,927 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 221.71 per share. | 24 Jun 2024 | 59 | 30,438 (0%) | 0% | 221.7 | 13,081 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 226.82 per share. | 24 Jun 2024 | 34 | 30,373 (0%) | 0% | 226.8 | 7,712 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 225.56 per share. | 24 Jun 2024 | 18 | 30,407 (0%) | 0% | 225.6 | 4,060 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 224.15 per share. | 24 Jun 2024 | 13 | 30,425 (0%) | 0% | 224.2 | 2,914 | Common Stock |
| CervoMed Inc | Jeffrey V. Poulton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 5,750 | 5,750 | - | - | Stock Option (Right to Buy) | |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 15,118 | 15,118 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 7,741 | 27,219 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Poulton Jeffrey V. | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2024 | 1,908 | 3,816 | - | - | Restricted Stock Units | |
| Alnylam Pharmaceuticals Inc | Poulton Jeffrey V. | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2024 | 1,908 | 20,052 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Poulton V. Jeffrey | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 154.54 per share. | 27 Feb 2024 | 247 | 19,805 (0%) | 0% | 154.5 | 38,171 | Common Stock |
| Alnylam Pharmaceuticals Inc | Poulton V. Jeffrey | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 155.45 per share. | 27 Feb 2024 | 194 | 19,611 (0%) | 0% | 155.4 | 30,157 | Common Stock |
| Alnylam Pharmaceuticals Inc | V. Poulton Jeffrey | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 156.38 per share. | 27 Feb 2024 | 115 | 19,496 (0%) | 0% | 156.4 | 17,984 | Common Stock |
| Alnylam Pharmaceuticals Inc | V. Jeffrey Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 157.29 per share. | 27 Feb 2024 | 17 | 19,479 (0%) | 0% | 157.3 | 2,674 | Common Stock |
| Alnylam Pharmaceuticals Inc | V. Jeffrey Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 158.00 per share. | 27 Feb 2024 | 1 | 19,478 (0%) | 0% | 158 | 158 | Common Stock |
| Alnylam Pharmaceuticals Inc | Poulton Jeffrey V. | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 3,278 | 19,151 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | V. Jeffrey Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 148.24 per share. | 15 Feb 2024 | 518 | 18,264 (0%) | 0% | 148.2 | 76,788 | Common Stock |
| Alnylam Pharmaceuticals Inc | V. Poulton Jeffrey | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 147.50 per share. | 15 Feb 2024 | 369 | 18,782 (0%) | 0% | 147.5 | 54,428 | Common Stock |
| Alnylam Pharmaceuticals Inc | V. Jeffrey Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 149.03 per share. | 15 Feb 2024 | 120 | 18,144 (0%) | 0% | 149.0 | 17,884 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 4,518 | 16,224 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 3,109 | 19,333 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 185.54 per share. | 03 Aug 2023 | 1,593 | 17,082 (0%) | 0% | 185.5 | 295,565 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 186.39 per share. | 03 Aug 2023 | 944 | 16,138 (0%) | 0% | 186.4 | 175,952 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 184.70 per share. | 03 Aug 2023 | 658 | 18,675 (0%) | 0% | 184.7 | 121,533 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 189.31 per share. | 03 Aug 2023 | 164 | 15,873 (0%) | 0% | 189.3 | 31,047 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 187.37 per share. | 03 Aug 2023 | 86 | 16,052 (0%) | 0% | 187.4 | 16,114 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 188.40 per share. | 03 Aug 2023 | 15 | 16,037 (0%) | 0% | 188.4 | 2,826 | Common Stock |
| Q32 Bio Inc. | Jeffrey V. Poulton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 23,000 | 23,000 | - | - | Option (Right to Buy) | |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2023 | 3,277 | 12,683 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 194.94 per share. | 26 Apr 2023 | 414 | 11,816 (0%) | 0% | 194.9 | 80,705 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 193.93 per share. | 26 Apr 2023 | 372 | 12,230 (0%) | 0% | 193.9 | 72,142 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 193.19 per share. | 26 Apr 2023 | 81 | 12,602 (0%) | 0% | 193.2 | 15,648 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 197.07 per share. | 26 Apr 2023 | 68 | 11,706 (0%) | 0% | 197.1 | 13,401 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 195.64 per share. | 26 Apr 2023 | 42 | 11,774 (0%) | 0% | 195.6 | 8,217 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2023 | 11,850 | 11,850 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2023 | 5,724 | 5,724 | - | - | Restricted Stock Units | |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 189.76 per share. | 03 Aug 2022 | 4,573 | 9,887 (0%) | 0% | 189.8 | 867,772 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2022 | 4,518 | 7,653 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2022 | 3,698 | 11,351 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2022 | 3,109 | 14,460 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 210.50 per share. | 03 Aug 2022 | 173 | 9,406 (0%) | 0% | 210.5 | 36,417 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 209.83 per share. | 03 Aug 2022 | 162 | 9,725 (0%) | 0% | 209.8 | 33,992 | Common Stock |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 209.88 per share. | 03 Aug 2022 | 146 | 9,579 (0%) | 0% | 209.9 | 30,642 | Common Stock |
| Q32 Bio Inc. | Jeffrey V. Poulton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Q32 Bio Inc. | Jeffrey V. Poulton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 18,000 | 18,000 | - | - | Option (Right to Buy) | |
| Alnylam Pharmaceuticals Inc | Jeffrey V. Poulton | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 23,200 | 23,200 | - | - | Stock Option (right to buy) | |
| Q32 Bio Inc. | Jeffrey V. Poulton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2020 | 36,000 | 36,000 | - | - | Option (Right to Buy) |